{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Chloroquinoxaline_Sulfonamide",
  "nciThesaurus": {
    "casRegistry": "97919-22-7",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A chlorinated heterocyclic sulfanilamide with potential antineoplastic activity and potential immunosuppressive activity.  Chloroquinoxaline sulfonamide poisons topoisomerase II alpha and topoisomerase II beta, thereby causing double-stranded breaks in DNA, accumulation of unrepaired DNA, and apoptosis.  This agent also exhibits lymphotoxicity by inhibiting lymphocyte activation in a cell cycle-specific manner.",
    "fdaUniiCode": "O0408QB48D",
    "identifier": "C982",
    "preferredName": "Chloroquinoxaline Sulfonamide",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1968"
    ],
    "synonyms": [
      "Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxalinyl)-",
      "Benzenesulfonamide, 4-amino-N-[5-chloro-2-quinoxalinyl]-",
      "CHLORSULFAQUINOXALINE",
      "CQS",
      "Chloroquinoxaline Sulfonamide",
      "Chloroquinoxaline sulfonamide",
      "Chlorsulfaquinoxaline",
      "chloroquinoxaline sulfonamide",
      "chlorosulfaquinoxaline"
    ]
  }
}